Inogen Inc. (INGN) intrinsic value & 10-year financials

Inogen Inc. (INGN) has a Graham intrinsic value of $17.37 per share. At $6.25 on Oct 17, 2026, the stock trades 64% below that value. Over the last 10 fiscal years revenue grew 6.5% a year to $295.3M, with an average return on invested capital of -19.5%.

Graham intrinsic value
$17.37
Share price (Oct 17, 2026)
$6.25
Price vs Graham value
64% below
Market cap
$166.3M
Revenue (FY2025)
$295.3M
Revenue growth (10-yr CAGR)
6.5%
ROIC (10-yr avg)
-19.5%
Free cash flow (FY2025)
-$13.7M

INGN 10-year financial history

Fiscal year Revenue Net income EPS (diluted) Free cash flow Operating margin ROIC
FY2025 $295.3M -$22.7M -$0.86 -$13.7M -10.2% -32.8%
FY2024 $278.8M -$35.9M -$1.52 $2.6M -15.3% -48.0%
FY2023 $251.6M -$102.4M -$4.42 -$8.5M -43.5% -96.1%
FY2022 $320.5M -$83.8M -$3.67 -$40.9M -26.6% -59.2%
FY2021 $311.7M -$6.3M -$0.28 $18.2M 3.0% 3.0%
FY2020 $280.2M -$5.8M -$0.27 $32.6M -4.3% -8.1%
FY2019 $340.5M $20.9M $0.94 $37.5M 5.8% 11.3%
FY2018 $336.0M $51.8M $2.30 $51.9M 11.3% 14.1%
FY2017 $225.5M $21.0M $0.96 $57.6M 12.2% 9.6%
FY2016 $168.2M $20.5M $0.97 $29.3M 13.6% 11.3%

Source: annual 10-K filings on SEC EDGAR. Figures in USD.

Executive summary

Inogen Inc has demonstrated mature, steady growth, with revenue compounding at 6.5% annually over the past decade.

Inogen Inc has historically struggled to out-earn its cost of capital, averaging just -32.8% ROIC.

Inogen Inc has not shown aggressive share repurchases (>10% retirement) or a major balance-sheet leverage increase (>50% net debt growth) over the 10-year window.

Benjamin Graham lens

Under Benjamin Graham's formula using SEC EDGAR fundamentals, Inogen Inc is modeled at 6.5% normalized earnings growth with a 5.1% bond-yield adjustment. The resulting Graham intrinsic value estimate is $17.37 per share.

INGN stock: frequently asked questions

What is the intrinsic value of Inogen Inc. (INGN) stock?

Using Benjamin Graham's revised formula, V = EPS × (8.5 + 2g) × 4.4 / Y, with reported diluted earnings per share, a 6.5% normalized growth rate (capped at 15%) and a 5.1% AAA corporate bond yield, INGN's intrinsic value is about $17.37 per share.

Is INGN stock undervalued?

At $6.25 (close on Oct 17, 2026), INGN trades 64% below its Graham value of $17.37. On Graham's terms that leaves a margin of safety. A formula is a starting point for research, not a recommendation.

How fast has Inogen Inc. grown?

Revenue went from $168.2M in fiscal 2016 to $295.3M in fiscal 2025, a compound annual growth rate of 6.5%. Net income was -$22.7M in fiscal 2025.

Does Inogen Inc. generate free cash flow?

Inogen Inc. generated -$13.7M of free cash flow (operating cash flow minus capital expenditures) in fiscal 2025. Free cash flow was positive in 7 of the last 10 reported years.

What is INGN's return on invested capital?

Average ROIC over the last 10 fiscal years was -19.5%, and average return on equity was -5.3%. Sustained ROIC above about 15% usually points to a durable competitive advantage.

Where does this INGN data come from?

From Inogen Inc.'s annual 10-K filings on SEC EDGAR, most recently filed Aug 7, 2026. Prices are end-of-day snapshots; valuations are formula outputs, not investment advice.

Similar orthopedic, prosthetic & surgical appliances & supplies stocks